|
|
Post by georgethenight2 on Jul 25, 2022 9:02:11 GMT -5
I guess I'm just frustrated. Mnkd developed a needle free epinephrine and did nothing with it. A lot of money is being spent to develop a different needle free version instead of partnering with mnkd. My guess is a technosphere powder gets into the bloodstream faster than an inhaled liquid. But I don't know if this is true or significant for epinephrine. I think we need to wait for the up coming conference call in August. If MC plays his hand to the favor of analysts and new investors alike, we might just see the second coming of the 4th July. A little booked DPI rev, growing Frez sales, possible other drugs on the horizon. Personally, I do understand the frustration, but recent that has been subsided by the feeling of "know what you own". A beauty of a stock. |
|
|
|
Post by cretin11 on Jul 25, 2022 9:51:27 GMT -5
I guess I'm just frustrated. Mnkd developed a needle free epinephrine and did nothing with it. A lot of money is being spent to develop a different needle free version instead of partnering with mnkd. My guess is a technosphere powder gets into the bloodstream faster than an inhaled liquid. But I don't know if this is true or significant for epinephrine. I think we need to wait for the up coming conference call in August. If MC plays his hand to the favor of analysts and new investors alike, we might just see the second coming of the 4th July. A little booked DPI rev, growing Frez sales, possible other drugs on the horizon. Personally, I do understand the frustration, but recent that has been subsided by the feeling of "know what you own". A beauty of a stock. George, do you think there will be some news about epinephrine in our upcoming August conference call? My understanding was that we’ve given up on epinephrine, but would like to be wrong about that. |
|
|
|
Post by hopingandwilling on Jul 25, 2022 10:09:44 GMT -5
Cretin, What is there to tell you, other than the fact they dropped their efforts to develop such a product! Here is a link to their pipeline of drugs they are working on. There is no mention of anything being done with epinephrine. They dropped this effort about two years ago! Sorry to be the bearer of bad news! mannkindcorp.com/pipeline/ |
|
|
|
Post by uvula on Jul 25, 2022 10:15:36 GMT -5
Cretin, What is there to tell you, other than the fact they dropped their efforts to develop such a product! Here is a link to their pipeline of drugs they are working on. There is no mention of anything being done with epinephrine. They dropped this effort about two years ago! Sorry to be the bearer of bad news! mannkindcorp.com/pipeline/Hoping, can you please provide a link backing up your claim about the fda requiring an epi pen? If not then it probably didn't happen. (Nothing personal. That's just how the internet works. ) There is no question that mnkd gave up on epinephrine. |
|
|
|
Post by cretin11 on Jul 25, 2022 10:23:12 GMT -5
OK, thanks. I was thrown off by George’s comment that “we need to wait for the up coming conference call in August.”
|
|
|
|
Post by hopingandwilling on Jul 25, 2022 11:03:01 GMT -5
Uvula,
Being honest! Your ‘demand’ for verification POs me! What difference does it make—read their current pipeline list and epinephrine is not listed. Go back six years ago, MannKind was constantly touting their goal of developing a competitor drug to Mylan’s Epi-Pen.
Google—MannKind Aggressively Moving Forward with inhalable epinephrine-January 2016.
Google—Los Angeles Time article September 2016—MannKind developing inhalable epinephrine to challenge Mylan’s EPI-Pen.
You won’t like this one—Google LFD’s May 21, 2021 Article—MannKind’s Moving in New Direction by Abandoning DPI Platform.
This is a good one—June 5, 2017—MannKind Engages Locust Walk to Explore Strategic Options for Non-Insulin Pipeline.
Simply Google --MannKind Working on Epineprine Product and you get the above links and more
I’m not going to wade through six years of MannKind’s touting they were working on an epinephrine product to suddenly admit they dropped the project. The simple point—MNKD is today not working on such a product—let that be the end of this story! I have better things to do with my time! Thank you!
|
|
|
|
Post by uvula on Jul 25, 2022 12:02:43 GMT -5
Uvula, Being honest! Your ‘demand’ for verification POs me! What difference does it make—read their current pipeline list and epinephrine is not listed. Go back six years ago, MannKind was constantly touting their goal of developing a competitor drug to Mylan’s Epi-Pen. Google—MannKind Aggressively Moving Forward with inhalable epinephrine-January 2016. Google—Los Angeles Time article September 2016—MannKind developing inhalable epinephrine to challenge Mylan’s EPI-Pen. You won’t like this one—Google LFD’s May 21, 2021 Article—MannKind’s Moving in New Direction by Abandoning DPI Platform. This is a good one—June 5, 2017—MannKind Engages Locust Walk to Explore Strategic Options for Non-Insulin Pipeline. Simply Google --MannKind Working on Epineprine Product and you get the above links and more I’m not going to wade through six years of MannKind’s touting they were working on an epinephrine product to suddenly admit they dropped the project. The simple point—MNKD is today not working on such a product—let that be the end of this story! I have better things to do with my time! Thank you! Holy crap. You apparently made up a story and stated it as fact. Then you get upset when someone asks for a source. No one is questioning the fact that mnkd dropped epinephrine. What I am questioning is the reason you provided for why they dropped epinephrine. |
|
|
|
Post by cretin11 on Jul 25, 2022 13:43:41 GMT -5
Hopingandwilling is correct about one thing. We won’t like reading that LFD article. Not easy admitting LFD was right.
|
|
|
|
Post by uvula on Jul 25, 2022 14:02:28 GMT -5
Hopingandwilling is correct about one thing. We won’t like reading that LFD article. Not easy admitting LFD was right. I'm confused. What lfd article? Did Hopings fda comment come from an lfd article? |
|
|
|
Post by sportsrancho on Jul 25, 2022 15:50:41 GMT -5
uvula - FWIW - I don't remember such a comment either. Now that I think about it neither do, I think there’s something off here…. unless that information wasn’t available to everyone. |
|
|
|
Post by cedafuntennis on Jul 25, 2022 22:38:28 GMT -5
MannKind was constantly touting their goal of developing a competitor drug to Mylan’s Epi-Pen. Google—MannKind Aggressively Moving Forward with inhalable epinephrine-January 2016. Google—Los Angeles Time article September 2016—MannKind developing inhalable epinephrine to challenge Mylan’s EPI-Pen. You won’t like this one—Google LFD’s May 21, 2021 Article—MannKind’s Moving in New Direction by Abandoning DPI Platform. This is a good one—June 5, 2017—MannKind Engages Locust Walk to Explore Strategic Options for Non-Insulin Pipeline. ----------- I clearly remember those releases from MNKD about a needle free alternative to EPI-Pen. Nothing about it now, unless it is one of the un-named projects listed. |
|
|
|
Post by mnkdfann on Jul 26, 2022 0:27:25 GMT -5
|
|
|
|
Post by akemp3000 on Jul 26, 2022 3:30:32 GMT -5
It does appear this horse is dead, at least for now. Looking forward to the Q2 call and something with more energy to discuss.
|
|
|
|
Post by diski58 on Jul 26, 2022 8:26:29 GMT -5
You might find the answer your looking for by googling a company called AQST. Google their June 15, 2022 article and later this year AQST will be doing head to head trials with epi pen. MannKind may not want to get into this area trying to crack another age old current “ standard of care”. AQST currently are in a legal battle and have been waiting for a response from the FDA for over 7 months that’s late as of now. Peppy, you will love their charts and graphs😉 |
|
|
|
Post by prcgorman2 on Jul 26, 2022 9:04:26 GMT -5
Uvula, Being honest! Your ‘demand’ for verification POs me! What difference does it make—read their current pipeline list and epinephrine is not listed. Go back six years ago, MannKind was constantly touting their goal of developing a competitor drug to Mylan’s Epi-Pen. Google—MannKind Aggressively Moving Forward with inhalable epinephrine-January 2016. Google—Los Angeles Time article September 2016—MannKind developing inhalable epinephrine to challenge Mylan’s EPI-Pen. You won’t like this one—Google LFD’s May 21, 2021 Article—MannKind’s Moving in New Direction by Abandoning DPI Platform. This is a good one—June 5, 2017—MannKind Engages Locust Walk to Explore Strategic Options for Non-Insulin Pipeline. Simply Google --MannKind Working on Epineprine Product and you get the above links and more I’m not going to wade through six years of MannKind’s touting they were working on an epinephrine product to suddenly admit they dropped the project. The simple point—MNKD is today not working on such a product—let that be the end of this story! I have better things to do with my time! Thank you! I observe that there was a change in CEO since the time MNKD touted development of an inhaled epinephrine in the pipeline. I think they're very wise to want a partner if for no other reason than to help defray costs, but potentially another deal like what was done for Tyvaso DPI and RLS103. i.e., paid for development, paid for manufacturing, paid royalties. I don't for a minute concede that LookingForDoodoo is "right". The management has full visibility to whether or not development should continue or be sold or sidelined.
The track record since 2016 is speaking for itself. MNKD did not go bankrupt. Instead, we have continued growth of revenue from Afrezza which finally seems to be getting back on track after the worst pandemic in 100 years, revenue from V-Go (which is good on the face of it at least), and unreported revenue from the 2nd TS-enabled FDA-approved product, Tyvaso DPI. Weekly sales of all 3 products might be $5M by EOY 2022. Imagine, 2023 with more than $200M in sales of Mannkind-manufactured products from a company on the brink of bankruptcy in 2016. Epi-what? How about epic? (Couldn't resist.)
|
|
